A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy.

ABSTRACT:

Background

Prostate cancer is a heterogenous disease, but once it becomes metastatic it eventually becomes treatment resistant. One mechanism of resistance to AR-targeting therapy is lineage plasticity, where the tumor undergoes a transformation to an AR-indifferent phenotype, most studied in the context of neuroendocrine prostate cancer (NEPC). However, activation of additional de- or trans-differentiation programs, including a gastrointestinal (GI) gene expression program, has been suggested as an alternative method of resistance. In this study, we explored the previously identified GI prostate cancer phenotype (PCa-GI) in a large cohort of metastatic castration-resistant prostate cancer (mCRPC) patient biopsy samples.

Methods

We analyzed a dataset of 634 mCRPC samples wit

SUBMITTER: Subramanian A 

PROVIDER: S-EPMC11185575 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature